Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)	0 Months Ended			12 Months Ended		15 Months Ended		0 Months Ended	12 Months Ended		3 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended			3 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Feb. 17, 2012	Jan. 19, 2012	May 26, 2010	Dec. 31, 2013 Segment	Dec. 31, 2012	Mar. 26, 2014 patent	Dec. 31, 2011	Jan. 14, 2014 Subsequent Event [Member]	Dec. 31, 2013 Maximum [Member]	Dec. 31, 2013 Minimum [Member]	Mar. 28, 2014 Common Stock [Member] Subsequent Event [Member]	Sep. 24, 2013 Series F Convertible Preferred Stock [Member]	Mar. 28, 2014 Series F Convertible Preferred Stock [Member] Subsequent Event [Member]	Sep. 24, 2013 Series C-1 Convertible Preferred Stock [Member]	Jan. 19, 2012 Series C-1 Convertible Preferred Stock [Member]	Sep. 23, 2013 Series C-1 Convertible Preferred Stock [Member]	Mar. 28, 2014 Series C-1 Convertible Preferred Stock [Member] Subsequent Event [Member]	Sep. 24, 2013 Series C-2 Convertible Preferred Stock [Member]	Dec. 31, 2012 Series C-2 Convertible Preferred Stock [Member]	Sep. 24, 2013 Private Placement [Member]	Sep. 24, 2013 Private Placement [Member] Common Stock [Member]	Sep. 24, 2013 Private Placement [Member] Series F Convertible Preferred Stock [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Securities purchase agreement, consideration received																					$ 10,000,000
Securities purchase agreement, number of shares issued																					1,928,620	3,250
Common stock, par value			$ 0.0001	$ 0.0001	$ 0.0001																$ 0.0001
Securities purchase agreement, price per share																					$ 3.50	$ 1,000
Private placement commission cost																				300,000
Securities purchase agreement, consideration received, net of commissions			6,003,000																	9,700,000
Convertible preferred stock, conversion right cap, percent of common stock ownership												9.99%
Convertible preferred stock, period of notice to increase or decrease conversion right cap												61 days
Convertible preferred stock, conversion price												$ 3.5088		$ 0.5800		$ 0.2347
Conversion cap of preferred stock									3.76%	0.00%
Amount paid upon exercise of redemption rights				2,900,000
Exercise of Series C-2 Warrants for Preferred Shares				0	500,000														500,000
Number of shares				500															500
Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract]
Accumulated deficit				(465,301,000)	(447,366,000)
Cash and cash equivalents				8,629,000	3,405,000		5,040,000
Securities Purchase Agreement date				May 24, 2010
Number of trading days				3 days
Percentage of issued and outstanding common stock				9.999%
Series of C-12 stock , Period of business days				10 days
Reverse stock split ratio	0.01	0.01						0.02
Estimated useful lives of the assets				5 years
Property and Equipment				2,233,000	2,186,000
Depreciation expense				$ 5,000	$ 0
Number of patents						5
Pre-vesting forfeitures were estimated for employees				0.00%	0.00%
Potentially dilutive securities for the exercise of outstanding stock options and warrants for common stock				17,500,000	90,000,000
Number of business segments for the development of pharmaceutical products				1
Exchange ratio, from class C-1 first issuance to C-1 second issuance															1
Stockholders redemption period				12 months
Conversion of stock, shares converted													184.190				1,622.343	557
Conversion of stock, shares issued											2,852,626			557